How to Verify a Clinical Trial for Yourself
You do not need a medical background to check whether a trial is real and what it actually measured. You need a registry identifier and about five minutes.
Claims about clinical trials circulate constantly, particularly around molecules that are not approved. Some are accurate. Some describe trials that exist but say something different from what is claimed. Some describe trials that do not exist at all.
Here is how to tell them apart, using free public tools and retatrutide as the worked example.
Step 1: find the identifier
Every registered trial has a unique identifier. On ClinicalTrials.gov, the world's largest registry,
it looks like NCT05929066 — the letters NCT followed by eight digits.
A credible claim about a trial gives you that identifier, or names the trial specifically enough that you can find it. If a page tells you “studies show” or “a recent trial found” and gives you no identifier, no sponsor and no publication, you have nothing to check.
The first red flag
An unverifiable claim is not necessarily false — but you cannot distinguish it from one that is. On a topic where sellers have a commercial interest in the claims they make, treat untraceable trial claims as unverified by default.
Step 2: open the record
Go to clinicaltrials.gov and paste the identifier into the search box. For trials conducted in India, the national register is the Clinical Trials Registry – India.
If no record appears, that is decisive: the trial is not registered where it claims to be.
Step 3: read seven fields
Registry records are long. These seven tell you almost everything that matters.
| Field | What to look for | TRIUMPH-1 |
|---|---|---|
| Sponsor | Who funds and runs it — relevant context, not disqualifying | Eli Lilly and Company |
| Phase | What kind of question it can answer | Phase 3 |
| Status | Recruiting, active, completed, terminated | Completed |
| Enrolment | How many, and whether actual or estimated | 2,335 (actual) |
| Study design | Randomised? Masked, and from whom? Against what? | Randomised, double-blind, placebo-controlled |
| Outcome measures | The pre-declared endpoints — the heart of the record | Percent change in body weight at week 80 |
| Eligibility | Who could take part — which bounds who results apply to | Obesity/overweight with comorbidity, without diabetes |
Outcome measures deserve particular attention. They are declared before results are known. If someone claims a trial proved something that is not among its outcome measures, that claim is about a secondary or post-hoc finding at best — and the registry record is how you catch it.
Step 4: check whether results exist
This is where many claims fall down. Four different things get conflated:
- Registered — the trial exists on paper. It may not have started.
- Completed — it finished. Results may not have been analysed or released.
- Reported — the sponsor has announced headline findings.
- Published — a journal has published it after independent peer review.
These are very different levels of evidence. Of the four retatrutide Phase 3 trials that have read out, as of 24 October 2026 only one — TRIUMPH-1 — has reached the fourth level, published in the New England Journal of Medicine in September 2026. The other three sit at level three.
Worth knowing
A registry record has a Study Results section, which may be empty even for a completed trial. An empty results section does not mean the trial failed. It often means results were reported elsewhere, or are not yet posted. Check the sponsor's announcements and the published literature as well.
Step 5: watch for the common traps
“Completed” read as “approved”
A completed trial is a finished trial. It is not a regulatory decision, and it creates no lawful route to obtain anything. Retatrutide has four completed Phase 3 trials and marketing approval in no country at all.
Phase confusion
A Phase 1 result in 45 healthy volunteers and a Phase 3 result in 2,339 participants are not comparable kinds of evidence. Always check the phase before weighing a finding.
A number without its context
“28.3% weight loss” is meaningless without the population, the duration, the comparator and the estimand. All four are in the registry record and the source announcement. Why the estimand in particular matters →
Trial authorisation presented as approval
A country permitting a trial has not approved a medicine for sale. These are separate decisions, and conflating them is the single most common error in claims about retatrutide in India. The distinction, in detail →
Try it now
Open NCT06662383. That is TRIUMPH-5, the head-to-head comparison of retatrutide against tirzepatide. Check its status, its enrolment, its primary outcome measure, and whether results have been posted.
You will find an active trial of 800 participants with a primary endpoint of percent body-weight change at week 80, and no results. Which means that anyone currently telling you which of those two molecules produces more weight loss is not drawing on this trial — because it has not reported.
That is the whole skill. Five minutes, and you can check it yourself.